A randomized prospective study of 191 patients with concomitant brain injury (CBI) of different severity has been carried out. All patients underwent surgery and received treatment in reanimation and intensive care departments. The main group consisted of 100 (52.4%) patients treated with cytoflavin in dosage 20-40 ml daily intravenously in drops during 10 days in addition to standard treatment. The comparison group included 91 (47.6%) patients who received standard treatment only. A positive effect of cytoflavin on clinical symptoms and laboratory characteristics of patients with CBI was identified. The decrease in severity measured with the APACHE II, higher activation of consciousness and improvement in the dynamics of neurological symptoms in these patients have resulted in the reduction in the duration of artificial lung ventilation and total hospital stay.